MARKET NEWS

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections From Ongoing Phase 3 Study
Taconic Biosciences Launches First & Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors for Improved Antibody Therapy Assessment
Catalent Expands Biologics Analytical Capabilities With New Laboratories at Center of Excellence in Kansas City, MO
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating Treatment of B-cell Acute Lymphoblastic Leukemia

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through our state-of-the art development and feasibility lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Acumen’s Anti-Amyloid Beta Oligomer Antibody Granted FDA Fast Track Designation for Alzheimer's Disease

Acumen’s Anti-Amyloid Beta Oligomer Antibody Granted FDA Fast Track Designation for Alzheimer's Disease

Acumen Pharmaceuticals, Inc. recently announced ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs), has been granted Fast Track designation for the treatment of early Alzheimer’s disease by….

BD, Biocorp Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

BD, Biocorp Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

BD (Becton, Dickinson and Company) and Biocorp recently announced they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies….

Jazz Pharmaceuticals & Zymeworks Announce Exclusive License Agreement

Jazz Pharmaceuticals & Zymeworks Announce Exclusive License Agreement

Jazz Pharmaceuticals plc and Zymeworks Inc. recently announced Jazz and Zymeworks’ subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire….

Societal CDMO Announces Signing of Multiple New CDMO Service Agreements

Societal CDMO Announces Signing of Multiple New CDMO Service Agreements

Societal CDMO, Inc. recently announced it has signed CDMO service agreements with two new customers. These contracts are focused on a range of analytical method, technical transfer, formulation, manufacturing and….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

  WHITEPAPERS & WEBINARS


WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 2 – Prefilled Syringes
November 9 – Injection Devices